Stock A185750 CHONG KUN DANG PHARMACEUTICAL CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Chong Kun Dang Pharmaceutical Corp.

Equities

A185750

KR7185750007

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
106,700 KRW 0.00% Intraday chart for Chong Kun Dang Pharmaceutical Corp. +2.11% -18.49%
Apr. 25 Tranche Update on Chong Kun Dang Pharmaceutical Corp.'s Equity Buyback Plan announced on January 23, 2024. CI
Jan. 23 Chong Kun Dang Pharmaceutical Corp. announces an Equity Buyback for KRW 15,000 million worth of its shares. CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • The company has a low valuation given the cash flows generated by its activity.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CHONG KUN DANG PHARMACEUTICAL CORP. Stock Chong Kun Dang Pharmaceutical Corp.
-18.49% 987M -
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.64% 43.3B
B-
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+21.25% 22.22B
B+
SANDOZ GROUP AG Stock Sandoz Group AG
+18.92% 15.43B -
CIPLA LIMITED Stock Cipla Limited
+20.14% 14.48B
B+
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+53.19% 12.72B
B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B - -
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.11% 6.71B
B+
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B - -
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.68% 5.5B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. A185750 Stock
  4. Ratings Chong Kun Dang Pharmaceutical Corp.